VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31

Vistagen Therapeutics, Inc.

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.20+0.00 (+1.55%)

Close on Oct 19, 2026

Market cap: $8.73M
P/E (TTM): –
Dividend yield: –

SEC filings

40 of Vistagen Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Oct 7, 2026	Oct 9, 2026	SEC EDGAR
Current report	8-K	Sep 25, 2026	Sep 25, 2026	SEC EDGAR
Current report	8-K	Sep 24, 2026	Sep 24, 2026	SEC EDGAR
Current report	8-K	Sep 22, 2026	Sep 22, 2026	SEC EDGAR
Current report	8-K	Sep 10, 2026	Sep 11, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Aug 14, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Aug 4, 2026	Aug 5, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jul 31, 2026	Jul 31, 2026	SEC EDGAR
Current report	8-K	Jul 29, 2026	Jul 31, 2026	SEC EDGAR
Current report	8-K	Jun 30, 2026	Jun 30, 2026	SEC EDGAR
Current report	8-K	Jun 16, 2026	Jun 17, 2026	SEC EDGAR
Annual report	10-K	Mar 31, 2026	Jun 15, 2026	SEC EDGAR
Current report	8-K	Jun 15, 2026	Jun 15, 2026	SEC EDGAR
Current report	8-K	Jun 9, 2026	Jun 9, 2026	SEC EDGAR
Current report	8-K	May 18, 2026	May 19, 2026	SEC EDGAR
Current report	8-K	May 12, 2026	May 12, 2026	SEC EDGAR
Current report	8-K	May 8, 2026	May 8, 2026	SEC EDGAR
Current report	8-K	Apr 22, 2026	Apr 28, 2026	SEC EDGAR
Current report	8-K	Apr 7, 2026	Apr 13, 2026	SEC EDGAR
Current report	8-K	Apr 1, 2026	Apr 2, 2026	SEC EDGAR
Current report	8-K	Mar 17, 2026	Mar 18, 2026	SEC EDGAR
Current report	8-K	Mar 16, 2026	Mar 16, 2026	SEC EDGAR
Current report	8-K	Mar 5, 2026	Mar 11, 2026	SEC EDGAR
Current report	8-K	Feb 13, 2026	Feb 20, 2026	SEC EDGAR
Quarterly report	10-Q	Dec 31, 2025	Feb 12, 2026	SEC EDGAR
Current report	8-K	Feb 12, 2026	Feb 12, 2026	SEC EDGAR
Current report	8-K	Feb 3, 2026	Feb 6, 2026	SEC EDGAR
Current report	8-K	Jan 9, 2026	Jan 9, 2026	SEC EDGAR
Current report	8-K	Dec 17, 2025	Dec 22, 2025	SEC EDGAR
Current report	8-K	Nov 28, 2025	Dec 3, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Nov 13, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Nov 3, 2025	Nov 4, 2025	SEC EDGAR
Current report	8-K	Oct 27, 2025	Oct 29, 2025	SEC EDGAR
Current report	8-K	Sep 9, 2025	Sep 15, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Proxy statement	DEF 14A	Sep 9, 2025	Jul 28, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Vistagen Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Jun 7, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VTGN.

Operating margin-2784.3% · median -986.8%

Net margin-2702.6% · median -702.1%

Company	Revenue	Growth
NRXP	$3.39M	–
UPB	$3.16M	+16.0%
VTGN	$2.50M	–
IGC	$1.12M	-15.4%
XENE	$0	-100.0%
DNTH	–	–

Company

Next earnings (est.): Nov 12, 2026, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: March 31
Employees: 41
Held by institutions: 26.5%
Auditor: KPMG LLP
SEC CIK: 1411685

Advertisement
300 × 250